BHVN
Biohaven Ltd.
NYSE · Healthcare · Biotechnology · US
$11.35
+5.29%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$11.01
From 52W high−37.33%
Volume1.69M
Market cap$1.71B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$11.01
From 52W high
−37.33%
Volume
1.69M
Market cap
$1.71B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.0x
P/E (TTM)
—
RSI (14)
40.1
MomentumView details →
1D Return
+5.29%
YTD Return
+1.06%
SummaryUpdated Jun 1, 2026
Biohaven Ltd. (NASDAQ:BHVN) is a clinical-stage biopharmaceutical company founded in 2022 as a spinoff from the original Biohaven Pharmaceutical Holding Company. The company emerged following Pfizer's acquisition of the original Biohaven's commercial migraine franchise for $11.6 billion, with the remaining pipeline assets and research programs forming the new independent entity. Biohaven focuses on developing innovative therapies for neurological and immunological diseases, positioning itself to address significant unmet medical needs in these therapeutic areas.
Similar companies
Latest newsMore news →
The U.S. FDA imposed a partial clinical hold on Biohaven's experimental epilepsy drug trials, pausing new patient enrollment after rodent findings.40d agoBiohaven entered into a licensing agreement with SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, for up to $795 million.55d ago